logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

The FDA Cleared Moderna's Coronavirus Vaccine for a Phase 2 Trial. The Stock Surged in Pre-market Hours

Moderna Coronavirus Vaccine Cleared for Phase 2 Moderna ( MRNA ) provided business updates for the first quarter of 2020 and highlighted pipeline progress. The current most important of the news is that the FDA has cleared Moderna’s coronavirus vaccine to...

Read More

May 7, 2020

0

Axsome Therapeutics: Treating Major Depressive Disorder. Vivos Therapeutics: Improving the Treatment of Obstructive Sleep Apnea

Axsome Therapeutics Inc and Major Depressive Disorder In a teleconference on August 20, 2021, the U.S. Food and Drug Administration ( FDA ) informed Axsome Therapeutics ( AXSM ) that its review of the new drug application ( NDA )...

Read More

August 23, 2021

0

Cassava Sciences Issued a Response to Claims Posted After Market Yesterday. See Also: Cassava Sciences Good News

Cassava Sciences Responds to Misleading Posts Cassava Sciences ( SAVA ) today issued a response to claims that were posted online yesterday after market hours. Cassava Sciences believes the claims made in this post regarding scientific integrity are false and...

Read More

August 25, 2021

0

Editas Medicine: Business Highlights and Financial Results Reported

Editas Medicine Reporting Editas Medicine ( EDIT ) reported business highlights and financial results for the first quarter of 2021. The reporting started with James C. Mullen, Chairman, President and Chief Executive Officer, Editas Medicine stating that Editas’ team is...

Read More

May 5, 2021

0

Bristol-Myers Squibb and bluebird bio Product Ide-Cel, Bb2121 and the FDA Refusal Letter. What Do We Expect?

Bristol-Myers Squibb and bluebird bio  Bristol-Myers Squibb ( BMY ) and bluebird bio ( BLUE ) received a Refusal to File letter from the United States FDA regarding the Biologics License Application ( BLA ), which was submitted in March...

Read More

May 13, 2020

0

Positive News for TCR2 Therapeutics - The U.S. FDA Granted Orphan Drug Designation to Gavo-Cel for Cholangiocarcinoma

TCR2 Therapeutics TCR2 Therapeutics ( TCRR )  is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from cancer. TCR2’s proprietary T cell receptor ( TCR ) Fusion Construct T cells (TRuC®-T cells)...

Read More

September 2, 2021

0

Moderna: Pricing of a Public Offering of 17,600,000 Shares at $76.00 Per Share

Moderna Inc: A Public Offering Moderna ( MRNA ) announced the pricing of an underwritten public offering of 17,600,000 shares of common stock at a public offering price of $76.00 per share, before underwriting discounts and commissions. Moderna has also granted the...

Read More

May 19, 2020

0

Interesting, Good News for Impel NeuroPharma and Migraine Sufferers

Impel NeuroPharma FDA Approval for TRUDHESA The U.S. Food and Drug Administration ( FDA ) approved Impel NeuroPharma ( IMPL ) product TRUDHESA (dihydroergotamine mesylate ( DHE )), previously known as INP104, a nasal spray for the treatment of acute...

Read More

September 3, 2021

0

Gilead Sciences and Galapagos NV: Good News from Filgotinib in Ulcerative Colitis

Gilead Sciences and Galapagos NV Announce Good News from Filgotinib Trial Gilead Sciences ( GILD ) and Galapagos NV ( GLPG ) announced positive topline results from the SELECTION trial - a randomized, double-blind, placebo-controlled, Phase 2b/3 trial evaluating the...

Read More

May 21, 2020

0

Why IVERIC bio Stock Rallied Today

IVERIC bio Stock Rally IVERIC bio ( ISEE ) stock rallied in early, premarket trading today as Stifel Nicolaus initiated a buy rating and a price target of $22. In premarket the stock was trading over $13.37, UP over $4...

Read More

September 10, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 117
  • 118
  • 119
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy